Superscript refers to 5. Tan. Clin Neuropharmacol. 2021;44:216
This references this specific research
14 Tan L, Peng J, Liu P, Wu Q. The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Clin Neuropharmacol 2021;44:216-21. [PMID: 34767325 DOI: 10.1097/WNF.0000000000000452] [Reference Citation Analysis]
This links to the following research document and note this is research only for documents up to 2019. This is not referencing any unblinded data!!
The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma remains controversial. We conduct a systematic review and meta-analysis to explore the influence of dendritic cell vaccine on treatment efficacy for newly diagnosed glioblastoma. We search PubMed, EMBASE, Web of science, EBSCO, and Cochrane library databases through December 2019 for randomized controlled trials assessing the efficacy and safety of dendritic cell vaccine for newly diagnosed glioblastoma. This meta-analysis is performed using the random effect model. Three randomized controlled trials are included in the meta-analysis. Overall, compared with control group for newly diagnosed glioblastoma, dendritic cell vaccine shows no substantial effect on median overall survival [standard mean difference, 0.11; 95% confidence interval (CI), -0.18 to 0.41; P = 0.45], median progression-free survival (standard mean difference, 0.12; 95% CI, -0.24 to 0.48; P = 0.50), progression-free survival rate [risk ratio (RR), 1.29; 95% CI, 0.82–2.04; P = 0.27], overall survival rate (RR, 1.29; 95% CI, 0.61–2.72; P = 0.50), or nervous system disorders (RR, 0.80; 95% CI, 0.59–1.08; P = 0.14). Dendritic cell vaccine may provide no obvious benefits for the newly diagnosed glioblastoma.
